medical decision support medical decision support
Sign In

Transarterial Chemoembolization (TACE) Resistance Individualized Prediction (TRIP) Score of Sciarra et al for Hepatocellular Carcinoma

Description

Sciarra et al developed a simple pathological score for evaluating response of a hepatocellular carcinoma to TACE (transarterial chemoembolization). This can help to identify a patient who should or should not get the therapy. The authors are from the University of Milan and Beaujon Hospital in Cichy, France.


Patient selection: hepatocellular carcinoma treated with transarterial chemoembolization (TACE).

 

Outcome: resistance (failure to respond), with > 50% residual tumor

 

Parameters:

(1) immunohistochemical staining for VEGF

(2) immunohistochemical vascular staining for CD34

 

Parameter

Finding

Points

VEGF

negative

2

 

positive

0

CD34

absent

0

 

present

1

 

TRIP score =

= SUM(points for the 2 immunostains)

 

Interpretation:

• minimum score: 0

• maximum score: 3

• A score of 2 or 3 was associated with residual tumor > 50% (resistance).

• A score of 0 or 1 was associated with residual tumor < 50%.

• The result depends only on the VEGF result.

 

Performance:

• The sensitivity was 89% and specificity 59%, with accuracy of 81%.


To read more or access our algorithms and calculators, please log in or register.

Specialty